Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Walter Carbone is active.

Publication


Featured researches published by Walter Carbone.


Science | 2016

CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency

Michael Bidinosti; Paolo Botta; Sebastian Krüttner; Catia C. Proenca; Natacha Stoehr; Mario Bernhard; Isabelle Fruh; Matthias Mueller; Débora Bonenfant; Hans Voshol; Walter Carbone; Sarah J. Neal; Stephanie M. McTighe; Guglielmo Roma; Ricardo E. Dolmetsch; Jeffrey A. Porter; Pico Caroni; Tewis Bouwmeester; Andreas Lüthi; Ivan Galimberti

Signal problems in autism spectrum disorder Autism spectrum disorders have many causes. Bidinosti et al. studied Phelan-McDermid syndrome (PMDS), one of the symptoms of which can be autism (see the Perspective by Burbach). The authors used neurons derived from these patients, as well as from mice, with the culprit gene disrupted and found that a chain of intracellular signals becomes imbalanced. Signaling and behavioral symptoms could be improved by a small-molecule therapeutic that inhibits a key kinase. Science, this issue p. 1199; see also p. 1153 Small-molecule therapeutics improve the social response in a mouse model of one of the autism spectrum disorders. [Also see Perspective by Burbach] SH3 and multiple ankyrin repeat domains 3 (SHANK3) haploinsufficiency is causative for the neurological features of Phelan-McDermid syndrome (PMDS), including a high risk of autism spectrum disorder (ASD). We used unbiased, quantitative proteomics to identify changes in the phosphoproteome of Shank3-deficient neurons. Down-regulation of protein kinase B (PKB/Akt)–mammalian target of rapamycin complex 1 (mTORC1) signaling resulted from enhanced phosphorylation and activation of serine/threonine protein phosphatase 2A (PP2A) regulatory subunit, B56β, due to increased steady-state levels of its kinase, Cdc2-like kinase 2 (CLK2). Pharmacological and genetic activation of Akt or inhibition of CLK2 relieved synaptic deficits in Shank3-deficient and PMDS patient–derived neurons. CLK2 inhibition also restored normal sociability in a Shank3-deficient mouse model. Our study thereby provides a novel mechanistic and potentially therapeutic understanding of deregulated signaling downstream of Shank3 deficiency.


eLife | 2016

Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62

Rowena DeJesus; Francesca Moretti; Gregory McAllister; Zuncai Wang; Phil Bergman; Shanming Liu; Elizabeth Frias; John Alford; John S. Reece-Hoyes; Alicia Lindeman; Jennifer Kelliher; Carsten Russ; Judith Knehr; Walter Carbone; Martin Beibel; Guglielmo Roma; Aylwin Ng; John A. Tallarico; Jeffery A. Porter; Ramnik J. Xavier; Craig Mickanin; Leon O. Murphy; Gregory R. Hoffman; Beat Nyfeler

SQSTM1 is an adaptor protein that integrates multiple cellular signaling pathways and whose expression is tightly regulated at the transcriptional and post-translational level. Here, we describe a forward genetic screening paradigm exploiting CRISPR-mediated genome editing coupled to a cell selection step by FACS to identify regulators of SQSTM1. Through systematic comparison of pooled libraries, we show that CRISPR is superior to RNAi in identifying known SQSTM1 modulators. A genome-wide CRISPR screen exposed MTOR signalling and the entire macroautophagy machinery as key regulators of SQSTM1 and identified several novel modulators including HNRNPM, SLC39A14, SRRD, PGK1 and the ufmylation cascade. We show that ufmylation regulates SQSTM1 by eliciting a cell type-specific ER stress response which induces SQSTM1 expression and results in its accumulation in the cytosol. This study validates pooled CRISPR screening as a powerful method to map the repertoire of cellular pathways that regulate the fate of an individual target protein. DOI: http://dx.doi.org/10.7554/eLife.17290.001


Methods of Molecular Biology | 2012

Genomic Profiling: cDNA Arrays and Oligoarrays

Francesco Gorreta; Walter Carbone; Dagania Barzaghi

The introduction of microarray technology, which is a multiplexed hybridization-based process, allows simultaneous analysis of a large number of nucleic acid transcripts. This massively parallel analysis of a cellular genome will become essential for guiding disease diagnosis and molecular profiling of an individual patients tumor. Nucleic acid based microarrays can be used for: gene expression profiling, single-nucleotide polymorphisms (SNPs) detection, array-comparative genomic hybridizations, comparisons of DNA-methylation status, and microRNA evaluation.A multitude of commercial platforms are available to construct and analyze the microarrays. Typical workflow for a microarray experiment is: preparation of cDNA or gDNA, array construction, hybridization, fluorescent detection, and analysis. Since many sources of variability can affect the outcome of one experiment and there is a multitide of microarray platforms available, microarray standards have been developed to provide industry-wide quality control and information related to each microarray. In this chapter, we review array construction, methodologies, and applications relevant to molecular profiling.


BMC Genomics | 2016

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

Michael K. Kiessling; Sven Schuierer; Silke Stertz; Martin Beibel; Sebastian Bergling; Judith Knehr; Walter Carbone; Cheryl de Valliere; Joelle Tchinda; Tewis Bouwmeester; Klaus Seuwen; Gerhard Rogler; Guglielmo Roma

BackgroundGenome-wide CRISPR-Cas9 dropout screens can identify genes whose knockout affects cell viability. Recent CRISPR screens detected thousands of essential genes required for cellular survival and key cellular processes; however discovering novel lineage-specific genetic dependencies from the many hits still remains a challenge.ResultsTo assess whether CRISPR-Cas9 dropout screens can help identify cancer dependencies, we screened two human cancer cell lines carrying known and distinct oncogenic mutations using a genome-wide sgRNA library. We found that the gRNA targeting the driver mutation EGFR was one of the highest-ranking candidates in the EGFR-mutant HCC-827 lung adenocarcinoma cell line. Likewise, sgRNAs for NRAS and MAP2K1 (MEK1), a downstream kinase of mutant NRAS, were identified among the top hits in the NRAS-mutant neuroblastoma cell line CHP-212. Depletion of these genes targeted by the sgRNAs strongly correlated with the sensitivity to specific kinase inhibitors of the EGFR or RAS pathway in cell viability assays. In addition, we describe other dependencies such as TBK1 in HCC-827 cells and TRIB2 in CHP-212 cells which merit further investigation.ConclusionsWe show that genome-wide CRISPR dropout screens are suitable for the identification of oncogenic drivers and other essential genes.


eLife | 2017

A comparative transcriptomic analysis of replicating and dormant liver stages of the relapsing malaria parasite Plasmodium Cynomolgi

Annemarie Voorberg-van der Wel; Guglielmo Roma; Devendra Kumar Gupta; Sven Schuierer; Florian Nigsch; Walter Carbone; Anne-Marie Zeeman; Boon Heng Lee; Sam Hofman; Bart W. Faber; Judith Knehr; Erica M. Pasini; Bernd Kinzel; Ghislain M.C. Bonamy; Tewis Bouwmeester; Clemens H. M. Kocken; Thierry T. Diagana

Plasmodium liver hypnozoites, which cause disease relapse, are widely considered to be the last barrier towards malaria eradication. The biology of this quiescent form of the parasite is poorly understood which hinders drug discovery. We report a comparative transcriptomic dataset of replicating liver schizonts and dormant hypnozoites of the relapsing parasite Plasmodium cynomolgi. Hypnozoites express only 34% of Plasmodium physiological pathways, while 91% are expressed in replicating schizonts. Few known malaria drug targets are expressed in quiescent parasites, but pathways involved in microbial dormancy, maintenance of genome integrity and ATP homeostasis were robustly expressed. Several transcripts encoding heavy metal transporters were expressed in hypnozoites and the copper chelator neocuproine was cidal to all liver stage parasites. This transcriptomic dataset is a valuable resource for the discovery of vaccines and effective treatments to combat vivax malaria.


Scientific Reports | 2017

Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells

David Estoppey; Jeffrey Hewett; Chantale T. Guy; Edmund Harrington; Jason R Thomas; Markus Schirle; Rachel Cuttat; Annick Waldt; Bertran Gerrits; Zinger Yang; Sven Schuierer; Xuewen Pan; Kevin Xie; Walter Carbone; Judith Knehr; Alicia Lindeman; Carsten Russ; Elizabeth Frias; Gregory R. Hoffman; Malini Varadarajan; Nadire Ramadan; John S. Reece-Hoyes; Qiong Wang; Xin Chen; Gregory McAllister; Guglielmo Roma; Tewis Bouwmeester; Dominic Hoepfner

Chemogenomic profiling is a powerful and unbiased approach to elucidate pharmacological targets and the mechanism of bioactive compounds. Until recently, genome-wide, high-resolution experiments of this nature have been limited to fungal systems due to lack of mammalian genome-wide deletion collections. With the example of a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, we demonstrate that the CRISPR/Cas9 system enables the generation of transient homo- and heterozygous deletion libraries and allows for the identification of efficacy targets and pathways mediating hypersensitivity and resistance relevant to the compound mechanism of action.


Proceedings of the National Academy of Sciences of the United States of America | 2018

Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy

Christoph Potting; Christophe Crochemore; Francesca Moretti; Florian Nigsch; Isabel Schmidt; Carole Manneville; Walter Carbone; Judith Knehr; Rowena DeJesus; Alicia Lindeman; Rob Maher; Carsten Russ; Gregory McAllister; John S. Reece-Hoyes; Gregory R. Hoffman; Guglielmo Roma; Matthias M. Müller; Andreas Sailer; Stephen B. Helliwell

Significance In mitophagy, damaged mitochondria are targeted for disposal by the autophagy machinery. PARKIN promotes signaling of mitochondrial damage to the autophagy machinery for engagement, and PARKIN mutations cause Parkinson’s disease, possibly because damaged mitochondria accumulate in neurons. Because regulation of PARKIN abundance and the impact on signaling are poorly understood, we performed a genetic screen to identify PARKIN abundance regulators. Both positive and negative regulators were identified and will help us to further understand mitophagy and Parkinson’s disease. We show that some of the identified genes negatively regulate PARKIN gene expression, which impacts signaling of mitochondrial damage in mitophagy. This link between transcriptional repression and mitophagy is also apparent in neurons in culture, bearing implications for disease. PARKIN, an E3 ligase mutated in familial Parkinson’s disease, promotes mitophagy by ubiquitinating mitochondrial proteins for efficient engagement of the autophagy machinery. Specifically, PARKIN-synthesized ubiquitin chains represent targets for the PINK1 kinase generating phosphoS65-ubiquitin (pUb), which constitutes the mitophagy signal. Physiological regulation of PARKIN abundance, however, and the impact on pUb accumulation are poorly understood. Using cells designed to discover physiological regulators of PARKIN abundance, we performed a pooled genome-wide CRISPR/Cas9 knockout screen. Testing identified genes individually resulted in a list of 53 positive and negative regulators. A transcriptional repressor network including THAP11 was identified and negatively regulates endogenous PARKIN abundance. RNAseq analysis revealed the PARKIN-encoding locus as a prime THAP11 target, and THAP11 CRISPR knockout in multiple cell types enhanced pUb accumulation. Thus, our work demonstrates the critical role of PARKIN abundance, identifies regulating genes, and reveals a link between transcriptional repression and mitophagy, which is also apparent in human induced pluripotent stem cell-derived neurons, a disease-relevant cell type.


Journal of Cell Biology | 2018

TRRAP is a central regulator of human multiciliated cell formation

Zhao Wang; Lindsey W. Plasschaert; Shivani Aryal; Nicole A. Renaud; Zinger Yang; Rayman Choo-Wing; Angelica D. Pessotti; Nathaniel D. Kirkpatrick; Nadire R. Cochran; Walter Carbone; Rob Maher; Alicia Lindeman; Carsten Russ; John S. Reece-Hoyes; Gregory McAllister; Gregory R. Hoffman; Guglielmo Roma; Aron B. Jaffe

The multiciliated cell (MCC) is an evolutionarily conserved cell type, which in vertebrates functions to promote directional fluid flow across epithelial tissues. In the conducting airway, MCCs are generated by basal stem/progenitor cells and act in concert with secretory cells to perform mucociliary clearance to expel pathogens from the lung. Studies in multiple systems, including Xenopus laevis epidermis, murine trachea, and zebrafish kidney, have uncovered a transcriptional network that regulates multiple steps of multiciliogenesis, ultimately leading to an MCC with hundreds of motile cilia extended from their apical surface, which beat in a coordinated fashion. Here, we used a pool-based short hairpin RNA screening approach and identified TRRAP, an essential component of multiple histone acetyltransferase complexes, as a central regulator of MCC formation. Using a combination of immunofluorescence, signaling pathway modulation, and genomic approaches, we show that (a) TRRAP acts downstream of the Notch2-mediated basal progenitor cell fate decision and upstream of Multicilin to control MCC differentiation; and (b) TRRAP binds to the promoters and regulates the expression of a network of genes involved in MCC differentiation and function, including several genes associated with human ciliopathies.


SLAS DISCOVERY: Advancing Life Sciences R&D | 2017

Screening of Intestinal Crypt Organoids: A Simple Readout for Complex Biology

Svenja Ley; Olaf Galuba; Adrian Salathe; Nicolas Melin; Alexandra Aebi; Monika Pikiolek; Judith Knehr; Walter Carbone; Martin Beibel; Florian Nigsch; Guglielmo Roma; Giovanni d’Ario; Susan Kirkland; Laure C. Bouchez; Caroline Gubser Keller; Tewis Bouwmeester; Christian N. Parker; Heinz Ruffner

Oral and intestinal mucositis is a debilitating side effect of radiation treatment. A mouse model of radiation-induced mucositis leads to weight loss and tissue damage, reflecting the human ailment as it responds to keratinocyte growth factor (KGF), the standard-of-care treatment. Cultured intestinal crypt organoids allowed the development of an assay monitoring the effect of treatments of intestinal epithelium to radiation-induced damage. This in vitro assay resembles the mouse model as KGF and roof plate-specific spondin-1 (RSPO1) enhanced crypt organoid recovery following radiation. Screening identified compounds that increased the survival of organoids postradiation. Testing of these compounds revealed that the organoids changed their responses over time. Unbiased transcriptome analysis was performed on crypt organoid cultures at various time points in culture to investigate this adaptive behavior. A number of genes and pathways were found to be modulated over time, providing a rationale for the altered sensitivity of the organoid cultures. This report describes an in vitro assay that reflects aspects of human disease. The assay was used to identify bioactive compounds, which served as probes to interrogate the biology of crypt organoids over prolonged culture. The pathways that are changing over time may offer potential targets for treatment of mucositis.


Nature Cell Biology | 2016

The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size

Lara Planas-Paz; Vanessa Orsini; Luke Boulter; Diego Calabrese; Monika Pikiolek; Florian Nigsch; Yang Xie; Guglielmo Roma; Adriana Donovan; Patricia Marti; Nicolau Beckmann; Michael T. Dill; Walter Carbone; Sebastian Bergling; Andrea Isken; Matthias Mueller; Bernd Kinzel; Yi Yang; Xiaohong Mao; Thomas B. Nicholson; Raffaella Zamponi; Paola Capodieci; Reginald Valdez; Daniel Rivera; Andreas Loew; Chinweike Ukomadu; Luigi Terracciano; Tewis Bouwmeester; Feng Cong; Markus H. Heim

Collaboration


Dive into the Walter Carbone's collaboration.

Researchain Logo
Decentralizing Knowledge